BEPACT- Lung: Impact of Patient Characteristics on Pneumo-oncologists NSCLC Systemic Treatment Decision in Belgium (BEPACT- Lung)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03959137|
Recruitment Status : Not yet recruiting
First Posted : May 22, 2019
Last Update Posted : May 24, 2019
The treatment landscape of metastatic NSCLC is rapidly evolving. There are new diagnostic and treatment options available in the coming months and years.
New combination treatments will give different solutions to pneumo-oncologists who might be guided by certain patient and tumor characteristics.
The link between patient and tumor characteristics in untreated stage IV NSCLC patients and systemic treatment needs further investigation, allowing the identification of possible treatment issues, data gaps and/or areas of improvement.
|Condition or disease||Intervention/treatment|
|Stage IV Non-small Cell Lung Cancer||Other: None - Common practice|
This is a multicenter, non-interventional, cross-sectional study. Consecutive patients with metastatic stage IV NSCLC selected for systemic treatment or best supportive care will be included in the trial at the time the patient signed the informed consent form (ICF). Patients that were selected for systemic treatment, should have received at least their first dose and a maximum of one cycle of the same treatment.
The pneumo-oncologist that treats the patient will fill in the CRF, indicating the systemic treatment option and the link with the variable categories that impacted the choice for a systemic treatment option.
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||BEPACT Lung: Impact of Patient Characteristics on Pneumo-oncologists NSCLC Systemic Treatment Decision in Belgium: A Cross-sectional Study|
|Estimated Study Start Date :||June 1, 2019|
|Estimated Primary Completion Date :||September 30, 2019|
|Estimated Study Completion Date :||October 31, 2019|
Primary study group
Stage IV untreated NSCLC
Other: None - Common practice
None - Common practice
- The study outcome is defined as the systemic treatment choice. [ Time Frame: Target 4 months, ]
Systemic treatment choices are defined as :
- Chemotherapy (chemo)
- Immunotherapy (IO)
- immuno combined therapies (IO+IO)
- IO+bevacizumab+chemo (IO+bev+chemo)
- best supportive care (BSC). There is no exposure in this study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03959137
|Contact: Hermine J Leroiemail@example.com|
|Contact: Mathias Schifflersfirstname.lastname@example.org|